Research advances on lenalidomide for the treatment of myelodysplastic syndromes
10.3760/cma.j.issn.1009-9921.2012.11.017
- VernacularTitle:雷利度胺治疗骨髓增生异常综合征的研究进展
- Author:
Yaomei WANG
- Publication Type:Journal Article
- Keywords:
Lenalidomide;
Myelodysplastic syndromes
- From:
Journal of Leukemia & Lymphoma
2012;21(11):697-699
- CountryChina
- Language:Chinese
-
Abstract:
The drugs used in myelodysplastic syndrome(MDS) are quite limited,and the prognosis of some types of MDS is worse.Recently,lenalidomide has gotten people' s attentions.Lenalidomide has been approved for the treatment of International Prognostic Scoring System (IPSS)-classified low-or intermediate-1-risk MDS associated with chromosome 5q31 deletion,with or without additional cytogenetic abnormalities.However,the mechanism of action of lenalidomide is still unclear.There are some research findings indicated that lenalidomide also has effect on others types of MDS,suggesting that it can be used more widely.The latest studies about efficacies of lenalidomide on MDS are reviewed in this article.
